Incyte to Trial Cancer Drug for Patients with COVID-19 Associated Cytokine Storm [Yahoo! Finance News]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance News
Global biopharma Incyte INCYThe collaborative study will be sponsored by Incyte in the United States and Novartis NVSAdditionally, given the urgent nature of the pandemic, Incyte intends to initiate a separate open-label emergency Expanded Access Program EAP) in the US. This will allow eligible patients with severe COVID-19 associated cytokine storm to receive the drug while it is still being investigated.“We recognize the significant and urgent medical need of patients with severe COVID-19 infection, and we are working with the FDA in an effort to rapidly advance the RUXCOVID and EAP studies,” said Steven Stein, M.D., Chief Medical Officer, Incyte.Mizuho Securities analystMara GoldsteinHowever, the analyst maintains a hold rating and $79 price target on the shares based on her view that meaningful catalysts for the shares are unlikely until 2021.Overall, INCY boasts a Moderate Buy analyst consensus rating with a $90 average analyst price target. As shares are currently trading down 1
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Trevi Therapeutics appoints new CFO [Seeking Alpha]Seeking Alpha
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and UnderstandingBusiness Wire
- Incyte Appoints Richard Hoffman as Executive Vice President and General CounselBusiness Wire
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- INCY's page on the SEC website